HIT Consultant February 23, 2023
What You Should Know:
– Tempus, the $10B artificial intelligence and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics, in which datasets of different omic groups – genomics, transcriptomics, epigenomics, and others are combined during analysis to improve research and enable new discoveries, including ones that would have been missed with a single method alone.
– This multi-omics approach is being used by Actuate Therapeutics in support of their Phase 1/2 oncology study of...
Today's Sponsors
Today's Sponsor